Exhibit 99.1

             FDA ALLOWS RESUMPTION OF LUPUS TRIALS WITH EPRATUZUMAB

    MORRIS PLAINS, N.J., Nov. 14 /PRNewswire-FirstCall/ -- Immunomedics, Inc.
(Nasdaq: IMMU), a biopharmaceutical company focused on developing therapeutic
monoclonal antibodies, today announced that their partner, UCB (Euronext
Brussels: UCB), has received notification from FDA that the clinical hold on
existing trials with epratuzumab in patients with lupus has been lifted.

    "We are pleased that the FDA has agreed to remove the clinical hold status
of the trials, and we plan to continue to work closely with UCB to make
epratuzumab available to patients who were in the suspended trials, and who
remain in urgent need," commented Cynthia L. Sullivan, President and Chief
Executive Officer of Immunomedics.

    Protocol amendments will now be submitted to Institutional Review Boards to
seek approval to treat patients who remain on the currently suspended studies,
and who are in need of re-treatment.

    The clinical hold status resulted from observations by UCB after a routine
audit of the end-stage manufacturing processes by Immunomedics, which resulted
in UCB's concerns regarding sterility assurance of the final product.

    About Immunomedics

    Immunomedics is a New Jersey-based biopharmaceutical company focused on the
development of monoclonal, antibody-based products for the targeted treatment of
cancer, autoimmune and other serious diseases. We have developed a number of
advanced proprietary technologies that allow us to create humanized antibodies
that can be used either alone in unlabeled or "naked" form, or conjugated with
radioactive isotopes, chemotherapeutics or toxins, in each case to create highly
targeted agents. Using these technologies, we have built a pipeline of
therapeutic product candidates that utilize several different mechanisms of
action. We have recently licensed our lead product candidate, epratuzumab, to
UCB for the treatment of all autoimmune disease indications worldwide. We have
retained the rights for epratuzumab in oncology indications for which UCB has
been granted a buy-in option. UCB has development, manufacture and
commercialization rights, and is responsible for all clinical trials evaluating
epratuzumab for the treatment of patients with moderate and severe lupus. At
present, there is no cure for lupus and no new lupus drug has been approved in
the U.S. in the last 40 years. We believe that our portfolio of intellectual
property, which includes approximately 108 patents issued in the United States,
and more than 250 other issued patents worldwide, protects our product
candidates and technologies. We also have a majority ownership in IBC
Pharmaceuticals, Inc., which is developing a novel dock and lock methodology,
and a new method of delivering imaging and therapeutic agents selectively to
disease, especially different solid cancers (colorectal, lung, pancreas, etc.),
by proprietary, antibody-based, pretargeting methods. Visit our web site at
http://www.immunomedics.com.

    About UCB

    Headquartered in Brussels (Belgium), UCB (http://www.ucb-group.com) is a
leading global biopharmaceutical company dedicated to the research, development
and commercialisation of innovative pharmaceutical and biotechnology products in
the fields of central nervous system disorders, allergy/respiratory diseases,
immune and inflammatory disorders and oncology - - UCB focuses on securing a
leading position in severe disease categories. Employing over 8,300 people in
over 40 countries, UCB achieved revenue of 2.3 billion euro in 2005. UCB is
listed on the Euronext Brussels Exchange.



    This release, in addition to historical information, may contain forward-
looking statements made pursuant to the Private Securities Litigation Reform Act
of 1995. Such statements, including statements regarding clinical trials,
out-licensing arrangements (including the timing and amount of contingent
payments), and capital raising activities, involve significant risks and
uncertainties and actual results could differ materially from those expressed or
implied herein. Factors that could cause such differences include, but are not
limited to, risks associated with new product development (including clinical
trials outcome and regulatory requirements/actions), competitive risks to
marketed products and availability of required financing and other sources of
funds on acceptable terms, if at all, as well as the risks discussed in the
Company's filings with the Securities and Exchange Commission. The Company is
not under any obligation, and the Company expressly disclaims any obligation, to
update or alter any forward-looking statements, whether as a result of new
information, future events or otherwise.

    For More Information:
    Immunomedics, Inc.
    Dr. Chau Cheng
    Associate Director
    Investor Relations & Business Analysis
    (973) 605-8200, extension 123
    ccheng@immunomedics.com

SOURCE  Immunomedics, Inc.
    -0-                             11/14/2006
    /CONTACT:  Dr. Chau Cheng of Immunomedics, Inc., Associate Director,
Investor Relations & Business Analysis, +1-973-605-8200, ext. 123,
ccheng@immunomedics.com/
    /Company News On-Call:  http://www.prnewswire.com/comp/113121.html/
    /Web site:  http://www.immunomedics.com
                http://www.ucb-group.com /
    (IMMU)